ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Commercial Labs Open Drive To Get More NIH Business, Including Grants

April 26, 1974

AACR, ASCO Continue Growth, Drop Idea Of “Cancer Week”

July 1, 1988

Battelle Wins Big Toxiology Contract

March 22, 1974

‘Rush To Downsize’ Is A Danger To NCI, Broder Warns In A Farewell Address

January 13, 1995

Also in this 8-page Issue: Safety Warnings Are Added to Labels for Epo and Avastin.

January 21, 2005

Public Health Service: Scientific Papers Become “Deliverables” In Own RFP

October 3, 1997